Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 675-680    DOI: 10.31083/j.ejgo.2020.05.5255
Original Research Previous articles | Next articles
Germline BRCA2 mutation is associated with greater progression-free survival in korean women with advanced high-grade serous ovarian cancer
Ji Geun Yoo1, Hae Nam Lee2, Sung Jong Lee3, Jin Hwi Kim4, Yong Seok Lee5, Ahwon Lee6, Soo Young Hur3, Keun Ho Lee3, *()
1Department of Obstetrics and Gynecology, Daejeon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Department of Obstetrics and Gynecology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
4Department of Obstetrics and Gynecology, Uijeongbu St. Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
5Department of Obstetrics and Gynecology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
6Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Download:  PDF(392KB)  ( 142 ) Full text   ( 18 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: In this study, the effect of a germline BRCA1/2 mutation on survival outcomes in Korean patients with advanced high-grade serous ovarian cancer was investigated. Methods: This multicenter retrospective study involved six Korean institutions that included 63 patients with International Federation of Gynecology and Obstetrics stages IIIC or IV high-grade serous ovarian cancer, diagnosed surgically between January 2010 and December 2015, and who had undergone a BRCA mutation test during their follow-up period. Median progression-free survival and 5-year overall survival were measured and compared according to BRCA1/2 mutation status using the Kaplan–Meier method. Results: Of 63 patients, 28 (44.4%) patients with germline BRCA1/2 mutations were identified. Nineteen (30.2%) patients were identified with a germline BRCA1 mutation, and nine (14.3%) patients with a germline BRCA2 mutation. The median progression-free survival of patients with wild-type BRCA, or a BRCA1 or BRCA2 mutation was 15, 17 and 37 months, respectively. Wild-type BRCA and germline BRCA2 mutation groups showed a significant difference in progression-free survival (p = 0.009); however, a significant difference was not found between wild-type BRCA and germline BRCA1 mutation groups (p = 0.262). Five-year overall survival rates of patients with wild-type BRCA, or a BRCA1 or BRCA2 mutation were 65.9%, 67.5% and 87.5%, respectively; significant differences was not found between the three groups. Conclusion: In Patients with advanced high grade serous ovarian cancer, germline BRCA2 mutation group showed a significantly longer median progression-free survival compared to wild-type BRCA group. Five-year overall survival rates were not significantly different among the three groups.
TRN: KCT0005463
Date of registration: 2020-10-12
Key words:  BRCA mutation      Korea      Multicenter study      Ovarian neoplasm      Survival analysis     
Submitted:  12 May 2019      Accepted:  30 October 2019      Published:  15 October 2020     
*Corresponding Author(s):  KEUN HO LEE     E-mail:  hohoho@catholic.ac.kr

Cite this article: 

Ji Geun Yoo, Hae Nam Lee, Sung Jong Lee, Jin Hwi Kim, Yong Seok Lee, Ahwon Lee, Soo Young Hur, Keun Ho Lee. Germline BRCA2 mutation is associated with greater progression-free survival in korean women with advanced high-grade serous ovarian cancer. European Journal of Gynaecological Oncology, 2020, 41(5): 675-680.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5255     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/675

[1] Ana Carolinne da Silva, Isac Souza Silva Rodrigues, Antônio Carlos Oliveira de Meneses, Eddie Fernando Candido Murta, Rosekeila Simões Nomelini. Ectopic pregnancy concomitant with borderline ovarian tumor[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 810-812.
[2] Ji Young Park, Gun Oh Chong, Yoon Hee Lee, Hyun Jung Lee, Chul Min Park, Eun Hye Lee, Dae Gy Hong. Transmembrane G protein–coupled receptor 30 (GPR30) gene polymorphisms in Korean Women with Ovarian Cancer: An experimental study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 556-562.
[3] Xiaofeng Xu, Xuan Zhou, Yijin Wang, Tao Liu, Jian Fu, Qian Yang, Jun Wu, Huaijun Zhou. Survival-associated transcriptome analysis in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 455-461.
[4] S. H. Chung, J. H. Sang. Is there a difference between synchronous multiple primary cancer and metastasis cancer?[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 480-483.
[5] N. Tug, M. Yassa, M. Akif Sargın, B. Dogan Taymur, K. Sandal, Ertunc Mega. Preoperative discriminating performance of the IOTA-ADNEX model and comparison with Risk of Malignancy Index: an external validation in a non-gynecologic oncology tertiary center[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 200-207.
[6] Dong-Hee Kim, Seung-Do Choi, Hae-Hyeog Lee, Tae-Hee Kim, Yeon-Suk Kim, Yesol Kim. The role of vitamin D up-regulated protein 1 in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 585-592.
[7] K. Chikazawa, S. Netsu, K. Akashi, Y. Suzuki, D. Hotta, R. Konno. Feasibility and tolerability of bevacizumab: a retrospective study in Japanese ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 790-794.
[8] Hui-Juan Zhang, Bao-Lin Qu, Ling-Ling Meng, Wei Yu, Lin Ma. Clinical observation of short-term efficacies of different hypofractionated radiation therapies after modified radical mastectomy for breast cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 524-532.
[9] R. Ulak, H.J. Seol, J.M. Lee. Epidemiological characteristics of gynecologic malignancies in Korean women[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 390-394.
[10] S. Proença, M. Mouraz, P. Conde, H. Santos e Pereira, F. Nunes. Malignant struma ovarii with synchronous papillary thyroid carcinoma: a rare diagnosis[J]. European Journal of Gynaecological Oncology, 2018, 39(1): 137-139.
[11] R.S. Nomelini, L.J. de Carvalho Oliveira, B.M. Tavares-Murta, E.F.C. Murta. Parameters of blood count and tumor markers: a retrospective analysis and relation to prognostic factors in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2017, 38(3): 364-367.
[12] A. Zwierzchowska, G. Panek, M. Gajewska, E. Barcz. Endometriotic lesions mimicking advanced ovarian cancer - A case report and a review of the literature[J]. European Journal of Gynaecological Oncology, 2017, 38(2): 303-307.
[13] T. Li, J. Tan, P. Cohen. A novel surgical technique for the large ovarian cystic mass – combined mini-laparotomy and laparoscopy[J]. European Journal of Gynaecological Oncology, 2016, 37(6): 766-770.
[14] A. Gómez-Portilla, R. Bustamante, E. López de Heredia, L.I. Lete, M. Cuadra, S. DomÍnguez. Growing teratoma syndrome: an unusual evolution of treated ovarian immature teratoma - a case report[J]. European Journal of Gynaecological Oncology, 2016, 37(5): 729-731.
[15] T.Y. Liu, Y.X. Zhu, P.Q. Ke, M. He, Y.C. Liang, S.Z. Yao. An unusual ovarian neoplasm diagnosed in a patient with rupture of unicornuate uterus during pregnancy: a case report[J]. European Journal of Gynaecological Oncology, 2016, 37(5): 732-735.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .